ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,996.66
1.00%
US Tech 100
20,877.20
1.72%
다우존스 지수
43,487.83
0.78%
Bitcoin
100,191.04
-0.81%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Incannex Healthcare Ltd (IXHL)

  7. Incannex Healthcare Ltd (IXHL) 뉴스

IXHL

Incannex Healthcare (IXHL)

Incannex Healthcare Ltd
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:IXHL
일자시간출처헤드라인심볼기업
2025/01/1106:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IXHLIncannex Healthcare Ltd
2024/12/1206:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IXHLIncannex Healthcare Ltd
2024/12/0914:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IXHLIncannex Healthcare Ltd
2024/12/0706:23Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:IXHLIncannex Healthcare Ltd
2024/11/2706:06Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:IXHLIncannex Healthcare Ltd
2024/11/1506:05GlobeNewswire Inc.Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business UpdatesNASDAQ:IXHLIncannex Healthcare Ltd
2024/11/1220:07Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:IXHLIncannex Healthcare Ltd
2024/11/1220:04Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:IXHLIncannex Healthcare Ltd
2024/11/0706:19Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:IXHLIncannex Healthcare Ltd
2024/11/0706:06Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:IXHLIncannex Healthcare Ltd
2024/11/0105:10Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:IXHLIncannex Healthcare Ltd
2024/10/2505:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IXHLIncannex Healthcare Ltd
2024/10/2505:48Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IXHLIncannex Healthcare Ltd
2024/10/2420:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IXHLIncannex Healthcare Ltd
2024/10/2420:30GlobeNewswire Inc.Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical OfficerNASDAQ:IXHLIncannex Healthcare Ltd
2024/10/2420:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IXHLIncannex Healthcare Ltd
2024/10/2205:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IXHLIncannex Healthcare Ltd
2024/10/1604:54Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IXHLIncannex Healthcare Ltd
2024/10/0105:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IXHLIncannex Healthcare Ltd
2024/10/0105:01GlobeNewswire Inc.Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business UpdatesNASDAQ:IXHLIncannex Healthcare Ltd
2024/09/3020:30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:IXHLIncannex Healthcare Ltd
2024/09/1021:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IXHLIncannex Healthcare Ltd
2024/09/1021:00GlobeNewswire Inc.Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena InvestorsNASDAQ:IXHLIncannex Healthcare Ltd
2024/09/1020:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IXHLIncannex Healthcare Ltd
2024/09/1020:00Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:IXHLIncannex Healthcare Ltd
2024/08/0520:30GlobeNewswire Inc.FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to ProceedNASDAQ:IXHLIncannex Healthcare Ltd
2024/07/3022:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IXHLIncannex Healthcare Ltd
2024/07/3020:30GlobeNewswire Inc.Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42XNASDAQ:IXHLIncannex Healthcare Ltd
2024/05/3021:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IXHLIncannex Healthcare Ltd
2024/05/3020:30GlobeNewswire Inc.Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep ApneaNASDAQ:IXHLIncannex Healthcare Ltd
 검색 관련기사 보기:NASDAQ:IXHL

최근 히스토리

FX
USDEUR
US Dollar vs Euro
COIN
XRPUSD
Ripple
NYSE
AXP
American Express
NYSE
CVX
Chevron
COIN
SOLUSD
Solana
AMEX
XLF
Financial Select Sector
NYSE
MRK
Merck
CCOM
US500
US 500
COIN
DOGEUSD
Dogecoin
CCOM
US30
US 30
COIN
AVAXUSD
Avalanche
NASDAQ
TSLA
Tesla
NASDAQ
GOOGL
Alphabet
SPI
SP500
S&P 500
USOTC
BASFY
BASF (QX)
USI
USTECH100
US Tech 100
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유